The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Pathfinder finds way forward in Mozambique

Wed, 22nd Mar 2023 10:30

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Pathfinder Minerals PLC, up 21% at 0.55 pence, 12-month range 0.35p - 0.95p. The Mozambique-focused natural resources firm enters into a conditional agreement with Acumen Advisory Group LLC for the sale of IM Mineral Ltd, its wholly-owned subsidiary. With it, Pathfinder disposes of the rights to bring a claim against the government of Mozambique for the expropriation of mining concession 4623C. Completion of the disposal is conditional upon shareholder approval at Pathfinder's general meeting on April 26. Completion will result in a payment of GBP2 million from AAG to Pathfinder, a commitment by AGG to begin legal proceedings against the government of Mozambique, and a contingent payment of USD24 million, or 20% of the net recoveries from any settlement or determination of the claim against the Mozambique government.

----------

Evgen Pharma PLC, up 4.9% at 4.04 pence, 12-month range 2.83p - 7.80p. The clinical-stage drug development company announces top line pharmacokinetic data for its placebo-controlled, dose-escalating, randomised Phase I/Ib clinical trial. The study aimed to provide further insight into the pharmacokinetic and pharmacodynamic characteristics of the new enteric coated tablet formulation of the company's lead asset SFX-01, as well as investigating how sulforaphane released from the tablet engages with targets of interest. Says sulforaphane was released by the enteric coated tablet beyond the acid environment of the stomach as predicted, and the levels of sulforaphane and its active metabolites in blood increased predictably with increasing doses. Notes that the total levels of sulforaphane and active metabolites in blood were in the range previously seen to be effective in pre-clinical experiments and clinical studies in a range of target diseases including breast cancer and glioblastoma.

----------

AIM - LOSERS

----------

Anpario PLC, down 27% at 225.00 pence, 12-month range 225.00p - 611.50p. The animal feed additive manufacturer reports a drop in annual profit due to declining demand and higher costs. Pretax profit falls 35% to GBP3.7 million in 2022 from GBP5.7 million the year prior, as its gross margin worsens to 43% from 49%. Revenue edges down to GBP33.1 million from GBP33.4 million. Says the year suffered from supply chain disruption and "significant and immediate" raw material and logistics price inflation. Explains this also hurt many of the farmers that are customers of Anpario. Farmers experienced input cost pressures, notably feed and energy, cutting their profitability and in some cases viability, according to Anpario. "Some farmers, particularly across the UK and Europe, decided to forgo unprofitable production which is now leading to specific food shortages in the retail channels. With less animals being reared the demand for animal feed and therefore additives is inevitably lower and partly explains the group's disappointing performance across Europe," it says. Nonetheless, firm proposes an increased final dividend of 7.35 pence, up from 7.0p the year prior.

----------

Mpac Group PLC, down 13% at 243.55 pence, 12-month range 210.00p - 534.00p. The automation ecosystem maker says pretax profit plunges to GBP200,000 in 2022 from GBP8.2 million in 2021, as cost of sales rises to GBP73.3 million from GBP65.4 million, and distribution expenses widen to GBP8.1 million from GBP6.8 million. Revenue, meanwhile, rises to GBP97.7 million from GBP94.3 million. Chief Executive Tony Steels explains that the year was characterised by "increased macro-economic uncertainty and unprecedented volatility in the global supply chain" which lengthened the lead time of customers' order placement and caused operational challenges. This resulted in lower order intake, reduced operational efficiency, and extended project build time-frames. Mpac adds that rising energy costs, higher interest rates, skilled labour shortages, and semi-conductor supply constraints are expected to continue into 2023, which it says "sets the context" for customer investments and decision-making. Separately, the firm announces that Adam Holland, its chief operating officer, will succeed Tony Steels as chief executive. Steels retires from the company after being CEO for more than six years. Says there will be a handover period, with Steels formally stepping down on May 17.

----------

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
25 Apr 2024 20:57

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
4 Apr 2024 17:24

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
19 Mar 2024 19:47

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Feb 2024 15:59

Evgen Pharma finds evidence of SFX-01 activity in colon cancer models

(Alliance News) - Evgen Pharma PLC on Tuesday said it found further evidence of SFX-01 activity in models of colon cancer.

Read more
19 Feb 2024 11:45

Evgen Pharma shares up on studies into SFX-01 product progressing well

(Alliance News) - Evgen Pharma PLC on Monday said the studies into its SFX-01 product were progressing positively regarding its activity in Glioblastoma cells.

Read more
9 Feb 2024 18:53

TRADING UPDATES: Apax opts against lifting offer; DCI enters loan deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
9 Feb 2024 17:02

LONDON MARKET CLOSE: FTSE 100 falls at end of tepid week

(Alliance News) - Stock prices in London closed lower on Friday, with the FTSE 100's losing streak extending to three days, as sentiment in Europe remains tetchy despite a largely stellar start to the day in New York.

Read more
16 Jan 2024 18:59

IN BRIEF: Evgen partner raises USD17.4 million to support pipeline

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Notes that its partner in autism spectrum disorder and other neurodevelopmental disorders Stalicla SA has announced that it has raised USD17.4 million, inclusive of a credit facility. This is to to support programmes on STP1, Stalicla's first asset in ASD, and a further asset in substance use disorders together with a biosampling and patient identification study in ASD. Evgen says it continues to work with Stalicla on delivery of a milestone payment for SFX-01 (Stalicla's STP2). Evgen says both parties are engaged in analysis and interpretation of Evgen's recent Phase 1b healthy volunteer PK/PD study and the implications for a future phase 2 trial in ASD. Evgen says it will provide updates on the status of the programme in "due course" and has not anticipated any milestone payments from Stalicla in its financial forecasting.

Read more
22 Dec 2023 18:06

IN BRIEF: Evgen appoints Toni Hanninen as permanent CFO

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Appoints Toni Hanninen as permanent chief financial officer, adding that he will now join the board as a director. Hanninen was appointed as interim CFO in September, having previously worked at Faron Pharmaceuticals Ltd. His permanent appointment becomes effective from January 1. Evgen also confirms that non-executive director, Susan Clement-Davies, will be retiring from the board.

Read more
31 Oct 2023 14:38

TRADING UPDATES: Acuity RM wins contract; Georgia Capital ups earnings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday, and not separately reported by Alliance News:

Read more
26 Oct 2023 11:08

Evgen upbeat on start of glioblastoma research project

(Sharecast News) - Clinical-stage drug developer Evgen Pharma announced on Thursday that it has partnered with Dr Marjolein Geurts, a neuro-oncologist at Erasmus University Medical Centre, to start a ground-breaking research initiative in glioblastoma.

Read more
19 Oct 2023 19:39

IN BRIEF: Evgen showcases importance of new enteric-coated formulation

Evgen Pharma PLC - Cheshire, England-based clinical stage drug developer - Highlights article published in respected industry publication the Medicine Maker, by its Chief Business Officer, Helen Kuhlman. The article, entitled the Sulforaphane Promise, focuses on the recent study of Evgen's new enteric-coated tablet formulation, and why enteric coatings are of particular importance for a stabilised complex such as SFX-01 that releases highly biologically active sulforaphane. The SFX-01 complex is vulnerable to breakdown in acid conditions and the enteric coat prevents acid attack in the stomach, releasing the drug in the ideal region - the small bowel. It also discusses the pharmacodynamic and pharmacokinetic data from the recent study, demonstrating the improvements of the tablet formulation over previous formulations of SFX-01.

Read more
5 Sep 2023 14:22

Evgen Pharma hires interim CFO from Faron, chair to retire this month

(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen.

Read more
15 Aug 2023 10:01

Evgen Pharma says trial shows new SFX-01 drug formulation is safe

(Alliance News) - Evgen Pharma PLC on Tuesday said final data from a trial of its SFX-01 therapy has shown a new formulation of the drug is safe.

Read more
2 Aug 2023 10:28

IN BRIEF: Evgen Pharma shares drop on ending of license agreement

Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focused on developing sulforaphane-based medicines - Terminates the patent and know-how license agreement for its Sulforadex sulforaphane stabilisation technology with partner JuvLife Ltd. The exclusive rights will be returned in the final quarter of 2023. The already received upfront payment is non-refundable.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.